Cour Pharmaceutical Development Company, Inc.

This study tested a new drug called CNP-104 in 42 adults with primary biliary cholangitis, a rare liver disease, who did not get better with standard treatments. The drug is designed to calm the immune system's attack on the bile ducts. The main goals were to check safety and see…